Eli Lilly's Zepbound, Mounjaro Sales Miss
This is a news story, published by Yahoo Finance, that relates primarily to Zepbound news.
Zepbound news
For more Zepbound news, you can click here:
more Zepbound newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
loss drug Zepbound. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest revenue news, Eli Lilly news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Mounjaro salesReuters
•Eli Lilly forecasts weaker Q4 sales of weight-loss drug, Mounjaro than expected
78% Informative
Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter .
Lilly said it expects 2025 sales between $58 billion and $61 billion .
Analysts were expecting revenue of $58.52 billion .
VR Score
89
Informative language
98
Neutral language
23
Article tone
formal
Language
English
Language complexity
49
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links